Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
04 mars 2024 07h00 HE
|
Apollomics Inc.
FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07 févr. 2024 07h00 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
19 janv. 2024 16h15 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
17 janv. 2024 16h30 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
03 janv. 2024 07h00 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address...
Apollomics to Present at the 2024 Biotech Showcase
02 janv. 2024 16h30 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
04 déc. 2023 07h00 HE
|
Apollomics Inc.
Treatment of NSCLC patients with MetExon14 skipping mutation with and without co-occurring MET amplification, reflecting “real-world”1 setting FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) --...
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
29 nov. 2023 07h30 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
28 nov. 2023 07h00 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
16 nov. 2023 08h30 HE
|
Apollomics Inc.
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer